深圳欣博盛生物科技有限公司

p75 NGF Receptor / CD271 antibody [ME20.4]

nerve growth factor receptor , CD271 , Gp80-LNGFR , TNFRSF16 , p75(NTR) , p75NTR

Cat, Human, Monkey, Pig, Racoon

Mouse

ELISA, FCM, IHC-Fr, IHC-P, IP, Neutralizing/Inhibition, RIA, WB

IgG1

human melanoma cell line WM245.

Monoclonal

ME20.4

Unpurified

Unconjugated

Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.

4°C

45

Liquid

Ascites, 15mM Sodium azide.

GeneTex

Neurotrophic factors control the survival, differentiation and maintenance of neurons in the peripheral and central nervous systems, and of other neural crest-derived cell types. Developing sympathetic neurons are absolutely dependent upon nerve growth factor (NGF) during the period of target competition in vivo. During this neonatal development window, NGF is believed to bind to its cognate receptors on the terminals of sympathetic neurons and to regulate their level of target innervation by two primary mechanisms. First, NGF stimulates terminal growth of sympathetic neurons thereby regulating the level of target innervation. Second, NGF, in conjugation with other neurotrophins, serves as discriminator allowing the elimination of neurons that have failed to sequester adequate target territory. Neurotrophic factors, like all polypeptide hormones, deliver their message to the cell interior via interaction with cell surface receptors. They interact with multicomponent receptors consisting of several distinct protein subunits. NGF binds to two different receptors; the low affinity surface receptor p75 neurotrophin receptor (also known as NGFR p75, p75NGFR, p75NTR) and the receptor tyrosine kinase TrkA, each with distinct signaling capabilities. Although multimeric receptor complexes and functional interactions between both receptors have been observed, it is clear that NGF can bind to and elicit biological actions through each of these two receptors independently. Other neurotrophins (GDNF, NT3 and NT4) are able to bind to NGFR p75 with similar affinities. However, the receptor is in fact able to distinguish among the different neurotrophins. Thus, for instance, NGF but not BDNF or NT3, activates a downstream signaling pathway through the receptor in Schwann cells and oligodendrocytes. The human NGFR p75 has a hydrophobic signal sequence, a single N-linked glycosylation site, four cysteine-rich repeat units of approximately 40 amino acids in the extracellular domain, a serine and threonine-rich region which might be O-linked glycosylated, a single transmembrane domain, and a 155 amino acid cytoplasmic domain. The extracellular domain of NGFR p75 has homology to the extracellular domains of B-lymphocyte activation molecule Bp50 and tumor necrosis factor receptor. It appears that NGFR p75 enhances the NGF binding affinity of the proto-oncogene product p140trk and also may modulate the kinase activity of p140trk and play a role in signal transducton. In addition, like other members of this family of receptors, NGFR p75 signals on its own and mediates apoptosis in certain cellular contexts. NGFR p75 contains a ideath domaini motif, which has been implicated in binding or activating death effector molecules. Specifically, neurotrophin binding to NGFR p75 stimulates generation of ceramide, activation and translocation of NF-kappaB to the nucleus, and enhancement of Jun kinase (JNK) activity. NGF and NGFR p75 have been the subject of extensive studies. Antibodies reacting specifically with NGFR p75 are useful tools in the detection and characterization of NGFR p75, to enhance our understanding of a wide range of phenomena in the development, plasticity and repair of the nervous system.